Clinical Trial Update: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial comparing olaparib plus temozolomide to the usual treatment for locally advanced or metastatic uterine corpus leiomyosarcoma that has pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Corpus Leiomyosarcoma

Drugs mentioned

• Lynparza (olaparib)
• Temodar (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-08